Document:

Exhibit 4.11

 

Loan Contract

 

Signing date: October 14, 2020

 

    1

     

    

 

Lender (Party A): Yan Haigang

 

Borrower (Party B): Shanxi Jinxuan Investment
Co., Ltd.

 

Whereas, Party B intends to borrow money from
Party A for its business and daily operation, now therefore, in consideration of the mutual promises and covenants set forth herein,
the Parties, intending to be legally bound, hereby make and enter into this Loan Contract.

 

I.           Loan
Amount

 

The Lender (Party A) will provide the Borrower
(Party B) with an amount of borrowing of RMB (in words) twenty million only (¥20,000,000).

 

II.          Loan
Term and Purpose

 

1.          The
loan term hereunder continues for 14 months, commencing on October 14, 2020 and ending on December 31, 2021. In the event of
any conflict between the actual arrival date of the loan and the starting date of the loan, the former shall prevail, and the loan term
shall be extended accordingly.

 

2.          The
loan shall be intended for Party B's business and daily operation expenses only.

 

III.         Loan
Interest Rate

 

The loan hereunder is the cash provided by Party
B's indirect controlling shareholder (Lender) to support the Party B's operations, bearing no interest.

 

IV.         Loan
Release

 

Both Parties agree that Party A shall remit the
loan to the Borrower's following account by bank transfer.

 

Designated receiving account number: 

 

Bank Name: Industrial Bank Co., Ltd. Taiyuan
Branch

 

Account Name: Shanxi Jinxuan Investment Co., Ltd.

 

V.          Representations
and Warranties of the Borrower

 

1.         The
Borrower (Party B), a civil entity incorporated under the law and legally existing, has all necessary capacities for rights and acts,
and is capable of performing its obligations hereunder and assuming corresponding liabilities in its own name.

 

2.          The
signing and performance of this Contract by the Borrower (Party B) is the real expression of the Borrower's intention, and is free of
any legal flaws as determined or authorized by the authorized decision-making and approval agency of the Borrower.

 

VI.         Rights
and Obligations of the Lender

 

The Lender (Party A) has the right to inspect
and supervise the Borrower (Party B) in respect of its loan usage, operating conditions, financial conditions, liabilities and external
guarantees and other information and conditions, in which the Borrower shall cooperate by faithfully providing related materials and reporting
related information in a timely manner, if required by the Lender.

 

VII.       Rights and Obligations of the Borrower

 

1.           The
Borrower shall not use the loan hereunder for purposes other than for that agreed herein.

 

2.           The
Borrower shall repay the principal of the loan hereunder subject to the time, amount and currency agreed herein.

 

3.           The
Borrower shall notify the Lender in writing within five days upon the occurrence or potential occurrence of any behavior or event that
may affect its ability to repay.

 

VIII.       Prepayment

 

Prepayment may, with the Lender's consent, be
made if so required by the Borrower.

 

IX.         Dispute
Settlement

 

Any dispute or controversy arising out of or relating
to this Contract shall be settled by the Parties through negotiation. Should such negotiation fail, such dispute or controversy may be
referred to the court having competent jurisdiction over the Lender. Those terms and conditions contained herein not in dispute shall
survive the dispute period.

 

    2

     

    

 

X.           Effectiveness

 

1.            This
Contract shall be established upon the signing and sealing by both Parties, effective from the date when the Lender pays the loan.

 

2.            Any
change to this Contract shall be made in writing by the Parties upon negotiation. The changed clause or agreement constitutes a part of
this Contract, with the same legal force and effect as this Contract. Except for the changed part, other parts hereof shall still be valid;
the original clause hereof shall still be valid until the changed part takes effect.

 

3.           This
Contract may be executed in three counterparts, one for the Lender, and two for the Borrower.

 

Signing at: Company Office, China Resources Building,
Wanbailin District, Taiyuan City, Shanxi Province

 

Signing on: October 14, 2020

 

Lender (Signature): Yan Haigang (fingerprinted)

 

	Borrower (Seal):	
    Seal of Shanxi Jinxuan Investment Co., Ltd.

    1401091007342

    

Legal Representative or Authorized Representative
(Signature): Guo Xiangyang

 

    3Document

Exhibit 10.2

Evelo Biosciences, Inc.

Amendment No. 2 to Consulting Agreement

This Amendment to that certain Consulting Agreement dated as of September 16, 2019 (as previously amended, the “Agreement”) is entered into by and between Evelo Biosciences, Inc., a Delaware corporation with a place of business located at 620 Memorial Drive, Cambridge, Massachusetts 02139, USA (the “Company”), and David Epstein, an individual residing at [***] (the “Consultant”).

WHEREAS, the Company and the Consultant desire to modify and extend the term of the Agreement to enable to Consultant to continue to provide services to the Company:

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged by the parties hereto, the parties agree as follows:

1.     Term.  Section 2 of the Agreement is amended and restated in its entirety to read as follows:

“This Agreement shall commence on September 16, 2019 and shall continue until and through June 30, 2022, unless sooner terminated in accordance with the provisions of Section 4 herein (such period, as it may be extended, being referred to as the “Consultation Period”).”

2.    Compensation.  A new Section 3.1A is added to the Agreement immediately after Section 3.1 of the Agreement and shall read as follows:

“3.1  Adjusted Consulting Fees.  Effective on June 30, 2021, and subject to approval by the Board of     Directors (the “Board”) of the Company, the Company shall award to the Consultant a number of Restricted Stock Units (as defined in the Company’s 2018 Incentive Award Plan, “RSUs”) having an aggregate grant date fair value equal to approximately $525,000, as determined by the Board in its discretion based on a ten-day trailing average of the closing price of a share of the Company’s common stock on the Nasdaq Global Select Market. The RSUs shall be granted under and shall be subject to the terms and provisions of the Company’s 2018 Incentive Award Plan (the “Plan”) and shall be granted subject to a restricted stock unit agreement. The RSUs shall vest in 12 substantially equal monthly installments following June 30, 2021, such that the RSUs shall be fully vested on June 30, 2022, subject to the Consultant continuing to provide Services to the Company pursuant to this Agreement through each such vesting date. Unless the Board otherwise determines, any portion of the RSUs which is unvested at the time of the termination of this Agreement shall be immediately forfeited upon such termination and shall not thereafter become vested. The RSUs shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Plan), to the extent outstanding at such time.  The provisions of Section 3.1 above shall cease to operate as of June 30, 2021 and thereafter the Consultant’s sole compensation (other than previously granted and then outstanding stock options) for his services as a consultant to the Company shall be as set forth in this Section 3.1A.”

3.    No Other Changes.  Except as expressly modified by this Amendment No. 2, all provisions of the Agreement shall remain unchanged and in full force and effect.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date written below.

															
		David R. Epstein			Evelo Biosciences, Inc.
					
	By:	/s/ David R. Epstein		By:	/s/ Balkrishan “Simba” Gill
					Balkrishan “Simba” Gill, Ph.D.
		Dated: April 9, 2021			President & Chief Executive Officer
					
					Dated: April 9, 2021Document

Exhibit 10.3

April 9, 2021

Mr. David R. Epstein
[***]
[***]

Re:  Amendment No. 2 to Letter Agreement

Dear David,

Reference is made to my letter dated as of September 16, 2019 addressed to you concerning your compensation for serving as the Chair of the Board of Directors of Evelo Biosciences, Inc. (as previously amended, the “Letter Agreement”).  This letter memorializes our recent discussion concerning an amendment to your compensation, and will become effective upon your signature below (the “Amendment”).

NOW, THEREFORE, the parties agree as follows:

1.  A new third paragraph of Section B (Equity Compensation) is added to the Letter Agreement and shall read as follows:

“Effective on June 30, 2021, and subject to approval by the Board, the Company shall award to you a number of Restricted Stock Units (as defined in the Company’s 2018 Incentive Award Plan, “RSUs”) having an aggregate grant date fair value equal to approximately $375,000, as determined by the Board in its discretion based on a ten-day trailing average of the closing price of a share of the Company’s common stock on the Nasdaq Global Select Market.  The RSUs shall be granted under and shall be subject to the terms and provisions of the Company’s 2018 Incentive Award Plan (the “Plan”) and shall be granted subject to a restricted stock unit agreement. The RSUs shall vest in 12 substantially equal monthly installments following June 30, 2021, such that the RSUs shall be fully vested on June 30, 2022, subject to your continuing service as the Chairman through each such vesting date. Unless the Board otherwise determines, any portion of the RSUs which is unvested at the time of the termination of your service as the Chairman shall be immediately forfeited upon such termination and shall not thereafter become vested. The RSUs shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Plan), to the extent outstanding at such time.  The provisions of Section A and the first two paragraph of Section B above shall cease to operate as of June 30, 2021 and thereafter your sole compensation (other than previously granted and then outstanding stock options) for service on the Board and its committees or subcommittees, including as Chairman, shall be as set forth in this third paragraph of Section B.”

2.  Except as expressly modified by this Amendment No. 2, the Letter Agreement shall remain unchanged and in full force and effect in accordance with its terms.

If the foregoing accurately sets forth our agreement, please countersign this letter in the space provide below.

620 Memorial Drive, 5th Floor • Cambridge, MA 02139 • 617-577-0300 •  http://www.evelobio.com

Mr. David R. Epstein
April 9, 2021
Page -2-

									
			Respectfully,
			
			  /s/ Balkrishan “Simba” Gill
			
			Balkrishan “Simba” Gill, Ph.D.
			President and Chief Executive Officer
			
	Agreed and Accepted:		
			
	/s/ David R. Epstein		
	David R. Epstein		
			

620 Memorial Drive, 5th Floor • Cambridge, MA 02139 • 617-577-0300 •  http://www.evelobio.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]